Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Telehealth providers in Georgia

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Telehealth prescribing is allowed in Georgia, but not asynchronous care. What Georgia requires of telehealth prescribers and pharmacies, plus listings with their verification status.

Georgia at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async not allowed
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Telehealth providers serving Georgia

Bodybuilding Peptides

Sponsored

Prescription peptides through an online assessment and a licensed provider review, shipped from a licensed U.S. compounding pharmacy.

Telehealth provider · 17 products · partner lists from $172 a month · Says it serves Georgia (not yet confirmed)

  • Prescription only, no research-use-only sales
  • Public cancellation and refund policy

We may earn a commission from these links.

Telehealth prescribing rules in Georgia

Georgia Composite Medical Board rule 360-3-.07 (Practice through electronic or other such means) allows treatment by electronic means by a Georgia-licensed physician, physician assistant, or advanced practice registered nurse who has personally seen and examined the patient, is acting at the request of a Georgia-licensed clinician who has, or is able to examine the patient using technology or peripherals that are equal or superior to an examination done personally. Board rule 360-3-.02(6) makes it unprofessional conduct to provide treatment by electronic means unless a history and physical examination of the patient has been performed by a Georgia licensee, with exceptions for on-call coverage and consultations. Rule 360-3-.02(5) makes it unprofessional conduct to prescribe controlled substances or dangerous drugs based solely on a consultation via electronic means, but does not prohibit prescribing a dangerous drug under a valid physician-patient relationship in accordance with O.C.G.A. 33-24-56.4, the Georgia Telehealth Act, an insurance statute that does not change the standard of care. Under O.C.G.A. 16-13-71 a dangerous drug is any non-scheduled drug that federal law allows to be dispensed only by prescription. This record reads that to include prescription-only GLP-1 drugs that are not scheduled; the statute does not name any drug. Both statutes were read on Justia's 2025 edition, not the official code. In its January 10, 2024 statement the Board said an in-person visit is not required for every prescription, but that its rules in general require a patient to be examined once in person before an initial prescription for controlled substances and/or dangerous drugs, that licensees should follow the Medical Practice Act and Board rules as of May 1, 2024, and that telemedicine providers must make diligent efforts to have patients examined in person annually. Out-of-state providers need a Georgia license. Rule 360-3-.07 has not changed since September 28, 2020 and rule 360-3-.02 was last amended effective August 27, 2024 (Administrative Code current through September 2, 2026). This record classifies asynchronous prescribing as not allowed because the Board's rules require an actual examination of a new patient, in person or with technology equal or superior to an in-person exam, before a first dangerous drug prescription, and the Board's own statement reads them as generally requiring one in-person exam. A questionnaire or other asynchronous review alone does not meet that. No Board rule names online questionnaires specifically. [2] [3] [7] [8] [9] [10]

Compounded GLP-1 access in Georgia

The practical Georgia barrier is the prescription itself. Rule 360-3-.07 lets a Georgia-licensed provider treat by telemedicine only if the provider has personally examined the patient, acts at the request of a Georgia licensee who has, or can examine the patient using technology equal or superior to an in-person exam. The Board said on January 10, 2024 that its rules in general require one in-person exam before an initial prescription for a dangerous drug. [3] [4] [8] [14]

Research use only sellers in Georgia

Only Georgia-licensed pharmacies and permitted nonresident pharmacies may dispense prescription drugs to Georgia patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law regardless of labeling and are not dispensed by a pharmacist. Georgia law also bars the sale directly: O.C.G.A. 26-3-10 provides that no person shall sell, deliver, offer for sale, hold for sale, or give away any new drug unless an application for it has become effective under section 505 of the federal act (or, for a drug not subject to the federal act, a state application has been filed with the State Board of Pharmacy), with an exemption only for drugs intended solely for investigational use by qualified experts and plainly labeled "For investigational use only." [5] [12] [15]

How to check a telehealth provider in Georgia

  1. Confirm the prescriber is licensed or registered to treat patients located in Georgia; the telehealth rules above explain what Georgia requires. [2] [3] [7] [8] [9] [10]
  2. Ask which pharmacy will fill the prescription and check it in the Georgia State Board of Pharmacy license lookup. [1] [5] [6] [11] [13]
  3. Get the full price in writing first: consult fees, membership fees, and the medication itself.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Georgia. [5] [12] [15]

Common questions in Georgia

Do I need an in-person visit to get a GLP-1 prescription by telehealth in Georgia?

Usually, or an exam using technology that is equal or superior to one. Georgia Composite Medical Board rule 360-3-.07 allows telemedicine prescribing when the provider has examined you in person, is acting at the request of a Georgia clinician who has, or can examine you with technology equal or superior to an in-person exam, and the Board has said its rules in general require one in-person exam before an initial dangerous drug prescription. No rule names online questionnaires, but a questionnaire alone does not meet that exam requirement. [3] [7] [8]

Did Georgia's pandemic telehealth flexibility end?

Yes. The Georgia Composite Medical Board announced in December 2023 that it was rescinding its COVID-era tele-prescribing position, extended the change to May 1, 2024, and now requires licensees to follow the Medical Practice Act and Board rules for prescribing. [4] [8]

What does an out-of-state pharmacy need to ship compounded peptides to Georgia?

A Georgia nonresident pharmacy permit under O.C.G.A. 26-4-114.1. Under Board rule 480-6-.02, a nonresident pharmacy that compounds must also submit an inspection report when it applies. Verify the permit on the Georgia Board of Pharmacy license lookup. [5] [6]

All peptide legal questions for Georgia

Sources

  1. [1]Georgia State Board of Pharmacy
  2. [2]Georgia Composite Medical Board
  3. [3]Georgia Composite Medical Board rule 360-3-.07, Practice through electronic or other such means (chapter 360-3)
  4. [4]Georgia Composite Medical Board: Board updates position on telehealth prescribing (December 7, 2023)
  5. [5]O.C.G.A. 26-4-114.1, Nonresident pharmacy permits
  6. [6]Georgia Board of Pharmacy rule 480-6-.02, Nonresident pharmacy permit
  7. [7]Georgia Composite Medical Board rule 360-3-.02, Unprofessional conduct defined (paragraph (6), treatment by electronic means; amended effective August 27, 2024), accessed 2026-09-22
  8. [8]Georgia Composite Medical Board: Board extends tele-prescribing flexibility until May 1 (January 10, 2024), accessed 2026-09-22
  9. [9]O.C.G.A. 16-13-71, Dangerous drug (definition), accessed 2026-09-22
  10. [10]O.C.G.A. 33-24-56.4, Georgia Telehealth Act (definitions; referenced in Board rule 360-3-.02(5); Justia 2025 edition), accessed 2026-09-30